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ponatinib was not detected in urine. In feces, major radio-
active components were ponatinib, M31 (hydroxylation), 
M42 (N-demethylation), and four methylated products 
accounting for 20.5, 17.7, 8.3, and 8.4% of the radioactive 
dose, respectively.
Conclusions Ponatinib was readily absorbed in humans, 
metabolized through multiple pathways and was eliminated 
mostly in feces.
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AP24592 (M19)  4-((4-methylpiperazin-1-yl)
methyl)-3-(trifluoromethyl)aniline
AP24600 (M14)  3-(imidazo[1,2-b]pyridazin-
3-ylethynyl)-4-methylbenzoic acid








Purpose Ponatinib is a novel tyrosine kinase inhibitor 
(TKI) specifically designed to inhibit native and mutated 
BCR–ABL. In the United States, ponatinib has received 
accelerated approval for adults with T315I-positive chronic 
myeloid leukemia (CML) or T315I (gatekeeper mutation)-
positive, Philadelphia chromosome-positive, acute lympho-
blastic leukemia (Ph + ALL), and patients with CML or 
Ph + ALL for whom no other TKI therapy is indicated. 
The objective of this phase 1, mass balance study was to 
evaluate the absorption, metabolism, and excretion of  [14C]
ponatinib in healthy subjects.
Methods A single 45-mg  [14C]ponatinib dose was admin-
istered orally to six healthy male volunteers, and absorp-
tion, metabolism, and excretion were assessed.
Results 86.6 and 5.4% of the dose was recovered in 
feces and urine, respectively, during days 0–14 postdose. 
Median time to maximal plasma radioactivity was 5 h and 
mean terminal elimination half-life of radioactivity was 
66.4 h. Ponatinib and its inactive carboxylic acid metabo-
lite M14, the two major circulating radioactive compo-
nents, accounted for 25.5 and 14.9% of the radioactivity 
in 0–24  h pooled plasma, with elimination half-lives of 
27.4 and 33.7  h, respectively. Major metabolites in urine 
were M14 and its glucuronides, which, together with other 
M14-derived metabolites, represented 4.4% of the dose; 
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AP32318 (M23)  4-(3-(imidazo[1,2-b]pyridazin-3-
ylethynyl)-4-methylbenzamido)-2-
(trifluoromethyl)benzoic acid
AUC  Area under the concentration–time 
curve
BQL  Below quantitation limit
Cmax  Maximum plasma concentration
CML  Chronic myeloid leukemia
CPM  Counts per minute
CV  Coefficient of variation
h  Hours
HPLC  High-performance liquid 
chromatography
LC/MS  Liquid chromatography/mass 
spectrometry
LC/MS/MS  Liquid chromatography with tan-
dem mass spectrometry
Ph + ALL  Philadelphia chromosome-positive 
acute lymphoblastic leukemia
SD  Standard deviation
t1/2  Terminal elimination half-life
TKI  Tyrosine kinase inhibitor
tmax  Time to maximal plasma 
concentration
TRA  Total radioactivity
Introduction
The use of tyrosine kinase inhibitors (TKIs) that tar-
get BCR–ABL has markedly improved the outcomes in 
patients with chronic myeloid leukemia (CML) [1]. Sec-
ond-generation TKIs, including nilotinib, dasatinib, and 
bosutinib, are frequently effective in patients who have 
developed resistance to first-line imatinib [1, 2]. The best-
characterized mechanism of resistance to first- and second-
generation TKIs is often mediated by mutations in the 
ABL kinase domain that disrupt TKI binding. A number of 
such resistance mutations have been characterized, among 
which the gatekeeper mutation T315I is uniformly refrac-
tory to first- and second-generation TKIs [3–5]. Ponatinib 
(AP24534) is a novel TKI that was developed using a 
computational and structure-based approach [6–8] to opti-
mally inhibit native BCR–ABL, as well as mutated forms 
of the protein, including the T315I gatekeeper mutant 
[3–5, 7]. Preclinical in vitro studies have demonstrated that 
ponatinib is a pan-BCR–ABL inhibitor, and can suppress 
the emergence of any single mutation at a concentration 
(40 nM) that can be achieved in patients [7, 9].
In phase 1 [9] and phase 2 (PACE) [10] trials, daily 
oral doses of 45  mg ponatinib demonstrated a positive 
benefit–risk in CML and Philadelphia chromosome-pos-
itive acute lymphoblastic leukemia (Ph + ALL) patients 
who experienced failure of prior TKIs, and these data 
supported the initial approval of ponatinib in the United 
States and the European Union. Ponatinib is the only 
approved oral TKI with clinical activity against the T315I 
mutant [7]. Single-dose and steady-state pharmacoki-
netic profiles of ponatinib have been characterized in the 
phase 1 study [9]. Ponatinib was readily absorbed fol-
lowing a 45-mg oral dose, with the steady-state maximal 
plasma concentration (Cmax) of 145 nM observed at 4–8 h 
(median time to Cmax was 4.8  h), and a mean terminal 
elimination half-life (t1/2) of approximately 22 h [9].
The objective of this phase 1, open-label, mass bal-
ance study was to evaluate the absorption, metabolism, 
and excretion of  [14C]ponatinib after administration of a 
single oral 45-mg dose in healthy male subjects. Herein, 
we provide detailed quantitative information about the 
total dose excreted, routes of excretion, and distribution 




The following nonradiolabeled reference compounds 
were provided by the Chemical and Process Develop-
ment Department, ARIAD Pharmaceuticals, Inc. (Cam-
bridge, MA, USA): ponatinib (AP24534), AP24600 
(M14), AP24592 (M19), AP32318 (M23), AP25047 
(M34), AP24734 (M36), and AP24567 (M42) (for struc-
tures, see Online Resource 5). The purity of the reference 
compounds was >95% as examined by liquid chromato-
graphy/mass spectrometry (LC/MS). Solvents and rea-
gents, all of analytical grade, were purchased from com-
mercial manufacturers.
Fig. 1  Structure of  [14C]ponatinib
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[14C]Ponatinib hydrochloride (Fig. 1) was synthesized 
(Aptuit LLC, Kansas City, MO, USA) and packed into 
size-1 gelatin capsules (ABC Laboratories, Inc., Colum-
bia, MO, USA) under Good Manufacturing Practices; 
each capsule contained ponatinib hydrochloride equiva-
lent to 15 mg of free base (36.7 µCi of radioactivity, spe-
cific activity 2.447 µCi/mg). The radiochemical purity of 
 [14C]ponatinib hydrochloride was 99.8%.
Subjects and drug administration
Recruiting of healthy subjects, housing, administration of 
 [14C]ponatinib, and collection of blood and excreta were 
completed at Celerion (Lincoln, NE, USA). The proto-
col and informed consent for this study were reviewed 
and approved by the Celerion Institutional Review Board. 
Informed consent was obtained from all individual partici-
pants and the study was conducted in accordance with the 
ethical standards of the Declaration of Helsinki.
Six healthy male volunteers, 25–45 years of age, with a 
mean body weight of 83.3 kg (range 64.5–94.4) and a mean 
body mass index of 26.9 kg/m2 (range 20.2–29.9) partici-
pated in the study. Each subject received a single oral dose 
of 45 mg  [14C]ponatinib (three 15-mg capsules, 110.1 μCi 
total) with 240 mL of water, in the fasted state on the morn-
ing of day 1. Whole blood, urine, and feces samples, and 
toilet tissue wipes, were collected up to the time of dis-
charge (11–14 days postdose, varied by subject). The sub-
ject release criterion was defined as follows: the combined 
urine and fecal radioactivity excretion for two consecu-
tive days should fall below 1% of the dose administered. 
Most patients were discharged 11–14 days following dose 
administration.
Sample collection, storage, and shipment
Detailed procedures on sample collection, storage, and 
shipment are described in Online Resource 1. A brief sum-
mary is provided here: 12 mL of whole blood was collected 
from each subject at various time points into  K2EDTA 
tubes; 2 mL of whole blood was aliquoted for total radio-
activity (TRA) analysis, and the rest of the blood was cen-
trifuged to obtain plasma for TRA analysis, metabolite 
identification, and liquid chromatography with tandem 
mass spectrometry (LC/MS/MS) quantitation of ponatinib 
and two metabolites (M14 and M42). Urine and feces col-
lected from each subject were pooled at predose and every 
24 h thereafter. Fecal homogenates were prepared by add-
ing water (four times the feces weight) and homogenizing. 
Following collection, samples were stored at −80 °C and 
shipped from the clinical site over dry ice to the following 
laboratories: plasma, to Advion Biosciences, Inc. (Ithaca, 
NY, USA) for quantitation of ponatinib and N-desmethyl 
metabolite M42 (AP24567); whole blood, plasma, urine, 
and feces, to ABC Laboratories for determination of TRA; 
and plasma, urine, and feces, to ARIAD Pharmaceuticals, 
Inc. (Cambridge, MA, USA) for metabolite profiling and 
quantitation of M14.
Determination of TRA
TRA analysis was carried out at ABC Laboratories. The 
radioactivity in plasma (duplicate per time point) and 
urine samples (triplicate per time point) was quantitated by 
direct counting in a Beckman LS6000SC or LS6500 liq-
uid scintillation counter (PerkinElmer Life and Analytical 
Sciences, Boston, MA, USA). Whole blood (duplicate per 
time point) and fecal homogenate (triplicate per time point) 
samples were oxidized, and the resultant 14CO2 was trapped 
in Carbosorb (Calgon Carbon Corporation, Pittsburgh, PA, 
USA) in combination with Permafluor, followed by liquid 
scintillation counting to determine the radioactivity. Indi-
vidual samples were counted for 5 min for whole blood and 
fecal matrices, and 10 min for plasma and urine matrices. 
Predose blood, plasma, urine, and feces samples served as 
respective control samples to determine and subtract the 
background radioactivity in the analysis.
LC/MS/MS quantitation of ponatinib and metabolites 
M14 (AP24600) and M42 (AP24567) in plasma
Ponatinib and M42 (AP24567) were determined using a 
validated LC/MS/MS method previously described [11]. 
M14 was quantitated using a different LC/MS/MS method 
(Online Resource 2). The pharmacokinetic analysis was 
carried out using  WinNonlin® v6.4 (Pharsight Corp., 
Mountain View, CA, USA).
Sample preparation of plasma, urine, and feces 
for metabolite profiling
Structural characterization of the metabolites and quanti-
tative determination (using radioactivity) of ponatinib and 
metabolites in pooled plasma, urine, and feces were carried 
out using LC/MS/MS methods coupled with offline radio-
activity detection.
For each subject, a 0–24  h pooled plasma sample was 
prepared according to the scheme outlined in the literature 
[12]. In addition, several pooled plasma samples across all 
subjects were prepared at these time points: 5, 10, 12, 36, 
and 48 h, and every 24 h thereafter until 240 h.
All pooled 0–24, 5, 10, 12, and 24  h plasma samples 
were processed as follows. Since the radioactivity in the 
plasma samples was low, unlabeled ponatinib and M14 
were added to enhance the recovery. Plasma samples 
(2.4 mL) were spiked with 1.2 μL of a methanol solution 
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containing ponatinib and M14 (each at 1 mg/mL) followed 
by 5  mL of ice-cold 1% formic acid in acetonitrile. The 
samples were vortexed for 30 min and centrifuged at 4500g 
at 4 °C for 6  min. The supernatants were transferred into 
new polypropylene tubes and kept on ice. The resulting 
plasma protein pellets were extracted twice to ensure good 
recovery and the extracts were combined. The combined 
extracts were loaded onto Ostro sample preparation plates 
(Waters Corporation, Milford, MA, USA), dried, eluted 
with 0.2 mL of cold acetonitrile, and all eluates were col-
lected and evaporated under nitrogen (TurboVap LV; Cali-
per Life Sciences, Hopkinton, MA, USA). The dry residues 
were reconstituted in 0.1 mL of methanol, and a 0.005-mL 
aliquot was removed for determination of radioactivity. The 
remainder of the supernatants were transferred to high-per-
formance liquid chromatography (HPLC) vials and stored 
at −80 °C until analysis.
Pooled post-24-h plasma samples were extracted using 
a slightly modified procedure. These samples were spiked 
with ice-cold 0.1% methanol solution containing deuter-
ated analogs (final concentration, 500 ng/mL) of ponatinib, 
M42, and M14. Appropriate volumes of formic acid were 
added to achieve a final concentration of 1%. Then, the 
samples were warmed to 37 °C and loaded to precondi-
tioned Oasis HLB cartridges (Waters Corporation, Milford, 
MA, USA). These columns were then washed with water, 
dried under vacuum, and eluted with methanol. The elu-
ates were collected and evaporated under nitrogen. The dry 
residues were reconstituted in 0.1 mL of methanol, and a 
0.005-mL aliquot was removed for determination of radio-
activity. The remainder of the supernatants were transferred 
to HPLC vials and stored at −80 °C until analysis.
Predose and 0–72-h urine samples (grand pool of all six 
subjects) were prepared. Urine samples (5 mL) were centri-
fuged, the supernatant was transferred to a 15-mL polypro-
pylene tube and placed on ice; the residues were extracted 
with 1 mL of methanol and the methanol extracts were 
added to the supernatants. The combined extracts were 
evaporated under nitrogen and reconstituted in 0.2  mL of 
methanol. A 0.010-mL aliquot of the reconstituted solu-
tion was removed for determination of radioactivity, and 
the remainder was transferred to HPLC vials and stored at 
−80 °C.
The predose and 0–144-h pooled fecal homogenate 
samples (grand pool of all subjects) were prepared. One-
gram samples of the fecal homogenates were transferred to 
50-mL polypropylene tubes, extracted with 4 mL of metha-
nol, and centrifuged (4500g). The resulting residues were 
extracted three more times (once with 2  mL of methanol 
and twice with 1  mL of methanol containing 1% formic 
acid) and centrifuged. All supernatants were combined 
and evaporated under nitrogen, and the residue was recon-
stituted with 0.5 mL of methanol, vortexed, sonicated, and 
centrifuged. A 0.010-mL aliquot of the supernatant was 
removed for determination of radioactivity, and the remain-
der of the supernatant was transferred to an HPLC vial and 
stored at −80 °C.
HPLC‑radiochromatographic profiling of ponatinib 
and its metabolites and structural characterization
A Finnigan Surveyor HPLC system (Thermo Fisher Scien-
tific Inc., San Jose, CA, USA), consisting of an LC pump 
plus an autosampler and a UV–Vis plus detector, was used 
mostly for profiling (except the post-24-h plasma samples, 
which were analyzed using a Dionex HPLC system). A 
 Phenomenex®  Gemini® C18, 5-μm, 3.0 × 100-mm column 
(Phenomenex Inc., Torrance, CA, USA) was used along 
with a C-12 guard column (4 × 2 mm). LC conditions were 
as follows: solvent A was 10 mM ammonium bicarbonate 
in water (pH 10.0) and solvent B was 100% methanol and 
the flow rate was 0.8 mL/min. The following gradient was 
employed (B%): 0–5  min (20%), 32  min (42%), 33  min 
(60%), 55  min (70%), 56–60  min (95%), and 62–70  min 
(20%).
Reconstituted solvent extracts (0.050–0.10  mL) of 
plasma, urine, or feces were injected onto the HPLC col-
umn. The post-column eluate was split after UV detection 
into two streams (0.64 and 0.16  mL/min). The 0.64-mL 
stream was diverted to a fraction collector (Gilson FX 204; 
Gilson Medical Electronics, Middleton, WI, USA) to be 
collected in 96-well plates at 0.16  min/well (ScintiPlates; 
PerkinElmer Life Sciences, Shelton, CT, USA), and the 
0.16-mL stream was directed to the mass spectrometer. The 
solvent in the 96-well plates was removed at 40 °C using 
a Genevac evaporator (Genevac, Inc., Stone Ridge, NY, 
USA).
The radioactivity counts per minute (CPM) in each well 
was determined using a MicroBeta scintillation counter 
(PerkinElmer Life and Analytical Sciences). The resulting 
CPM vs. time data were processed using Excel (Microsoft 
Corporation, Seattle, WA, USA). The CPM in each well 
was background-subtracted (using the average CPM val-
ues of the blank region of the HPLC run). Radiochroma-
tographic profiles were obtained by plotting the resulting 
net CPM values against time after injection. Radioactive 
peaks in the chromatographic profiles were identified, and 
the radioactivity in each peak was summed and reported as 
a percentage of TRA in the HPLC run.
The remaining eluate stream of 0.16 mL/min from the 
HPLC runs was diverted to the inlet of the mass spec-
trometer. The samples were analyzed using a heated 
electrospray ionization probe. Full-scan positive ion MS 
data were collected using Finnigan Exactive  (MS1) or 
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Q-Exactive  (MS1 and  MS2) mass spectrometers (Thermo 
Fisher Scientific Inc.) Exact conditions are described in 
the Online Resource 3.
Results
Concentration–time profiles of TRA, ponatinib, 
and metabolites in plasma
The concentration–time profiles of TRA, ponatinib, and 
metabolites M14, M23, and M42 are illustrated in Fig. 2, 
and the pharmacokinetic parameters are listed in Table 1. 
TRA in plasma was determined using liquid scintillation 
counting. Ponatinib and its metabolites M14 and M42 
were quantitated using LC/MS/MS methods, whereas 
M23 was quantitated by radiochromatography. Cmax of 
TRA, ponatinib, M14, and M42 in plasma was observed at 
2–12 h postdose and maximal levels of M23 were observed 
substantially late at 36 h. At 144 h postdose, plasma TRA 
was ~39 nM, whereas ponatinib, M14, M23, and M42 lev-
els were below 2.4, 2.4, BQL (3 nM), and 0.2 nM, respec-
tively. The elimination curves of ponatinib, M14, M23, 
and M42 are nearly parallel, indicating that their terminal 
elimination half-lives are very similar. The TRA appeared 
to decrease in plasma with a longer half-life than that of 
the parent drug. This was likely due to the contribution of 
non-identifiable radioactive degradation products slowly 
released from deep body compartments (ponatinib has a 
large volume of distribution, Vz/F = 1101 L).
Excretion and mass balance in urine and feces
The cumulative recovery of radioactive dose in urine, feces, 
and total dose excreted is presented in Fig.  3. The total 
radioactive dose recovered during 0–336 h was 92.0%, with 
86.6 and 5.4% of the dose recovered in feces and urine, 
respectively. The cumulative recovery in feces during 
0–144 h represented 91% of the TRA in feces. Therefore, 
metabolite profiling of feces samples was carried out using 
0–144 h pool. The urinary metabolite profiling was carried 
out using the 0–72-h pool as it contained 84% of the total 
urinary TRA.
Metabolite characterization by LC/MS/MS
The metabolite structures were characterized by mass spec-
tral fragmentation patterns (Online Resource 5) and, where 
possible, were confirmed by comparison of chromato-
graphic retention times and mass spectra of the reference 
standards (AP24600 [M14], AP32318 [M23], AP25047 
[M34], AP24734 [M36], and AP24567 [M42]). The  MS2 
fragmentation pattern of ponatinib (AP24534) is shown in 
Fig. 4. The molecular ion of ponatinib  [MH]+ was observed 
at m/z 533.2278, and the main fragment ions were observed 
Fig. 2  Mean plasma concentration–time profiles of TRA, ponatinib, 
and metabolites M14 (AP24600), M23 (AP32318), and M42 
(AP24567). Error bars represent SD; n = 6. TRA in plasma was 
determined using liquid scintillation counting. Ponatinib and its 
metabolites (M14 and M42) were quantitated using LC/MS/MS 
methods, whereas M23 was quantitated by radiochromatography 
[M23 (nM) = ponatinib concentration (nM)  ×  radioactivity ratio of 
M23/ponatinib]. LC/MS/MS liquid chromatography with tandem 
mass spectrometry. SD standard deviation, TRA total radioactivity
Table 1  Pharmacokinetic 
parameters of TRA, ponatinib, 
and metabolites M14 and M42 
in human plasma
AUC0–144 area under the plasma concentration–time curve from time 0–144 h of last quantifiable concen-
tration, AUC0–∞ area under the plasma concentration vs. time curve from time 0–infinity, Cmax maximal 
observed plasma concentration, CV coefficient of variation, SD standard deviation, t1/2 terminal elimination 
half-life, tmax time to maximal plasma concentration, TRA total radioactivity
a All pharmacokinetic parameters are geometric means except tmax values, which are medians; all pharma-
cokinetic parameters are based on analysis of 0–144 h plasma
Pharmacokinetic  parametersa TRA Ponatinib M14 M42
Cmax, nM (% CV) 251.6 (24.6) 109.6 (23.1) 5.0 (40.9) 107.2 (36.6)
AUC0–144, h nM (% CV) 13,841.9 (18.8) 3476.1 (27.9) 169.0 (28.6) 1606.4 (25.0)
AUC0–∞, h nM (% CV) 17,526.3 (19.7) 3571.8 (29.1) 180.9 (27.7) 1795.2 (25.5)
t1/2, h (± SD) 66.4 (13.5) 27.4 (5.5) 33.7 (8.6) 56.0 (39.7)
tmax, h (range) 5 (5–5) 5 (5–12) 5 (5–8) 2 (2–4)
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at m/z 433.1269, 260.0814 (100% abundance), 232.0855, 
205.0749, and 101.1075. The fragment ion at m/z 433.1269 
was formed by the neutral loss of N-methylpiperazine moi-
ety (100 amu). The amide bond cleavage produced a major 
fragment ion at m/z 260.0814, and further fragmentation of 
m/z 260.0814 resulted in fragments of m/z 232.0855 and 
205.0749 by successive losses of CO (28 amu) and HCN 
(27 amu). The ion at m/z 101.1075 is from the protonated 
N-methylpiperazine group. The fragmentation pattern of 
ponatinib was compared with those of its metabolites for 
identification of metabolites (Online Resource 5). The pro-
posed metabolite structures were supported by exact mass 
measurements of their  [MH]+ ions. The metabolites of 
ponatinib predominantly underwent fragmentation analo-
gous to that of the parent drug, which allowed localization 
of structural changes in the metabolites. Metabolite profil-
ing of plasma, urine, and feces is shown in Fig. 5, and the 
proposed metabolic pathways are depicted in Fig.  6. The 
metabolites fall into two broad categories: metabolites of 
intact ponatinib (oxidation, demethylation, sulfation, glu-
curonidation, methylation, and extensive metabolism of 
the piperazine moiety) and those of amide hydrolysis prod-
uct M14 and its further metabolites (glucuronidation and 
esterification).
Metabolite profiling of plasma
A representative radiochromatographic profile of metab-
olites in pooled 0-24  h plasma after administration of 
 [14C]ponatinib to healthy human volunteers is presented 
in Fig.  5a. Preliminary radiochromatographic profil-
ing and mass spectral data analyses indicated ponatinib 
and its amide hydrolysis acid metabolite M14 as the two 
largest radioactive components in the plasma. Radioactiv-
ity recovered during preliminary extractions was in the 
range of 50–70%. Having established the presence of M14 
and ponatinib in plasma, a modified extraction scheme 
was developed to maximize the extraction of radioactiv-
ity. Unlabeled ponatinib and M14 were spiked into plasma 
samples prior to extraction, which resulted in an increase in 
radioactivity recovery (92.4%). Since unlabeled standards 
were spiked, this method did not affect the quantitation by 
radiochromatography. Moreover, this modified procedure 
had little impact on the interpretation of the data because 
the qualitative identification of ponatinib and M14 was 
established before this modified method was adopted.
Metabolite profiles of pooled plasma samples taken at 
several time points during 0–144 h were qualitatively simi-
lar among the six subjects (Table  2 and Online Resource 
4). In the 0–24-h pooled plasma, ponatinib accounted for 
25.5% of the TRA. The metabolites M14 and M14 glucu-
ronide (M15) accounted for 14.9% and 3.4% of the plasma 
radioactivity, respectively (Table  2). Ponatinib despiper-
azinyl acid (M23), ponatinib glucuronide (M29), hydroxy-
ponatinib glucuronide (M24), N-desmethyl ponatinib 
(M42), and ponatinib N-oxide (M36) accounted for 7.0, 
6.0, 2.1, 0.5, and 0.5% of the plasma radioactivity, respec-
tively. In addition to M14, the amide hydrolysis would 
yield a putative aromatic amine (M19). However, M19 was 
not observed in any human samples, but only trace levels 
of acetylated M19 (M22, nonradioactive) were observed in 
MS traces in human plasma, urine, and feces. Radiochro-
matograms of the 5-, 10-, and 12-h plasma extracts are 
shown in Online Resource 4A, 4B, and 4C, respectively, 
and the corresponding data are presented in Table  2. In 
these samples, ponatinib, the glucuronides M14 and M15, 
M23, and ponatinib glucuronide M29 were also observed 
(similar to the 0–24 h plasma).
As a result of low levels of radioactivity in post-24-h 
plasma samples, quantitation by radioactivity was limited 
to ponatinib and two of the metabolites (Online Resources 
4D–4I; Table  2). The 36-h plasma radiochromatogram 
showed three prominent peaks that were identified as M14, 
M23, and ponatinib. Radiochromatograms of 72- and 96-h 
postdose plasma showed only M23 and ponatinib. No dis-
tinct radioactive peaks were observed in the extracts of 
plasma samples collected at 120 and 144 h postdose. Using 
accurate mass data and the available synthetic standard, 
the structure of M23 was unequivocally established as 
ponatinib N-despiperazinyl acid.
Metabolite profiling of urine
Representative radiochromatographic profile of metabo-
lites in pooled 0–72 h human urine is shown in Fig. 5b, 
and the percent distributions of ponatinib and its 
Fig. 3  Cumulative recovery of radioactive dose in excreta up to 
264 h. Error bars represent SD; n = 6. TRA in urine was determined 
using liquid scintillation counting. TRA in feces was determined by 
oxidization followed by liquid scintillation counting. SD standard 
deviation, TRA total radioactivity
513Cancer Chemother Pharmacol (2017) 79:507–518 
1 3
metabolites in human urine are presented in Table  3. 
Ponatinib was observed only at trace levels in urine. 
The overall urinary metabolite profile was dominated 
by M14 and its glucuronides, M15 and M16. In 0–72  h 
urine, M14, M15, and M16 accounted for 5.6, 28.1, and 
19.8% of the TRA, respectively (accounting for 53.5% of 
the total urinary radioactivity). Hydroxyponatinib glucu-
ronide (M24) contributed 5.1% to the TRA in urine. A 
cluster of metabolites eluted at 35–41  min comprising 
several metabolites: M25, M29, M30, M31, M32, M33, 
M34, M35, M36, M38, M39, M41, and other co-eluting 
metabolites. Individually, each metabolite in the cluster 
accounted for approximately 0.1–3.0% of the urinary 
radioactivity and, together, these metabolites accounted 
for 14.0% of the TRA in urine.
Metabolite profiling of feces
Representative radiochromatographic profile of metabo-
lites in pooled 0–144 h human feces is shown in Fig. 5c, 
and the percent distribution of ponatinib and its metabo-
lites is presented in Table 3. In 0–144 h feces, ponatinib 
accounted for 23.7% of the radioactivity. Hydroxy-
ponatinib (M31) and N-desmethyl ponatinib (M42) were 
the two largest radioactive metabolites in human feces, 
and accounted for 20.4 and 9.6% of the radioactivity, 
respectively (Table 3). Several metabolite peaks that were 
not well resolved chromatographically formed a cluster 
(M23 cluster, eluting at 33.0–37.6 min) and cumulatively 
accounted for 17.2% of the fecal radioactivity; how-
ever, each metabolite from the cluster only contributed 
Fig. 4  MS2 product ion 
spectrum of ponatinib. Inset: 
m/z values displayed in the 
fragmentation scheme are based 
on theoretical exact mass of the 
fragments
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approximately 2–3%. Other metabolites observed in 
feces were M32, M33, M35, M36, M38, M39, and M41 
(each <0.5%), and cumulatively, they contributed 2.1% 
of the total fecal radioactivity. There were four ponatinib 
metabolites (M43, M46, M47, and M49) with an exact 
molecular weight of  [MH]+ 547.2426 differing by 1.7 
mmu from a theoretical mass difference for a putative 
methylated metabolite. Together, these four methylated 
metabolites contributed 9.7% to the total fecal radioactiv-
ity (Table 3). No M14-derived metabolites were detected 
in feces.
Fig. 5  Biotransformation profiles of  [14C]ponatinib in pooled a plasma, b urine, and c feces. cpm counts per minute
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Fig. 6  a Proposed biotransfor-
mation pathways of ponatinib in 
humans and b proposed major 
biotransformation and elimina-
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Discussion
Following oral administration of a single dose of 45  mg 
 [14C]ponatinib to healthy volunteers, 92% of the dose was 
recovered 0–336 h postdose; a majority (86.6%) of the dose 
was recovered in feces and only a small percentage (5.4%) 
was recovered in urine. Low levels of radioactivity were 
observed in plasma even at 264 h postdose plasma, whereas 
ponatinib, M14, and M42 levels in plasma were at or below 
detectable limits 144 h postdose.
In 0–24 h human plasma, ponatinib and M14 were the 
major radioactive components, with M14 present at 14.9% 
of the plasma TRA. M23, the product of N-dealkylation 
of the despiperazinyl group, was a minor metabolite (7% 
of plasma TRA). Dealkylation of the piperazinyl group 
has been observed in an another TKI, imatinib [13]. M42, 
Table 2  Percent distribution of 
ponatinib and its metabolites in 
human plasma
TRA total radioactivity
a Only radioactive peaks containing ≥2.0% TRA in the metabolite profile of plasma are listed, except M36 
and M42, which were major in vitro metabolites. Radiochromatographic profiles of plasma beyond 96-h 
collection did not reveal any distinct peaks. “–” values less than 0.5% are not reported
Metabolite ID Retention time (min) % Distribution in  plasmaa
5 h 10 h 12 h 0–24 h 36 h 48 h 72 h 96 h
M14 16.6–20.1 29.0 10.8 12.8 14.9 2.4 – – –
M15 20.2–21.8 2.0 2.4 – 3.4 – – – –
M23 32.1–34.2 – 3.4 2.4 7.0 3.9 5.4 10.7 6.0
M24 33.5–35.0 – – – 2.1 – – – –
M29 38.2–39.2 3.0 4.3 6.0 6.0 – – – –
M36 38.2–42.5 ~0.5 ~0.5–1.0 ~0.5–1.0 ~0.5–1.0 – – – –
M42 44.8–49.8 ~0.5–1.0 ~0.5–1.0 ~0.5–1.0 ~0.5–1.0 – – – –
Ponatinib 47.8–53.2 42.4 36.3 51.5 25.5 4.2 9.4 12.8 13.2
Table 3  Percent distribution 
of ponatinib and its major 
metabolites in urine and feces 
after administration of a single 
oral 45-mg dose of  [14C]
ponatinib to humans
TRA total radioactivity
a Only peaks containing >1.5% of the TRA were included
b M25–M41 cluster: metabolites include M25, M29, M30, M31, M32, M33, M34, M35, M36, M38, M39, 
M41, and other co-eluting unknown metabolites individually accounting for approximately 0.1–3% of the 
urine radioactivity
c M23 (N-despiperazinyl acid) cluster: Metabolites include M23, M24, M25, M26, M27, and other co-elut-
ing unknown metabolites individually accounting for approximately 0.1–3% of the fecal radioactivity
d M32–M35 cluster: Metabolites include M32, M33, M35, and other co-eluting unknown metabolites indi-
vidually accounting for approximately 0.1–1.0% of the fecal radioactivity
Matrix [collection interval] Metabolite ID Retention time (min) % Distribu-
tion in matrix
% of total 
radioactive 
dose
Urinea [0–72 h] M14 16.6–20.1 5.6 0.3
M15 20.2–21.8 28.1 1.51
M16 22.5–24.5 19.8 1.07
M24 33.5–35.0 5.1 0.27
M25–M41  clusterb 35.0–41.0 14 0.75
Ponatinib 47.8–53.2 Trace levels <0.05
Fecesa [0–144 h] M23  clusterc 32.1–37.6 17.2 14.9
M31 38.0–38.9 20.4 17.7
M32–M35  clusterd 38.5–39.5 2.1 1.8
M36/M38 39.2–40.5 3.2 2.8
M39/M41 40.1–41.5 3 2.6
M42/M43 44.8–49.8 9.6/3.4 8.3/2.9
Ponatinib/M46, M47 47.8–54.0 23.7/3.2 20.5/2.8
M49 55.4–57.5 3.1 2.7
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a major in vitro metabolite (data not shown), was present 
only at <1% in circulation. The same metabolites were 
also observed in the post-24-h plasma samples, and no new 
ponatinib metabolites were observed after 24 h. Both M14 
and M23 were shown to be inactive against BCR–ABL in 
in vitro studies (kinase as well as cellular activity screens) 
(data not shown). The metabolites in urine were mostly 
M14 and its glucuronides. M14 was generated due to 
hydrolysis of the amide bond of ponatinib. Amide hydrol-
ysis has been observed in human studies of flumatinib, a 
nilotinib analog being tested for its efficacy in patients with 
CML [14]. Since M14 and derived metabolites accounted 
for 81% of the TRA in urine (and none in feces), and the 
total dose recovered in urine was 5.4%, it was estimated 
that the amide hydrolysis accounted for 4.4% of the dose; 
therefore, amide hydrolysis represented a minor pathway of 
ponatinib metabolism. In human feces, ponatinib accounted 
for 23.7% of the radioactivity and was extensively metabo-
lized, and most of the metabolites were generated from the 
biotransformation of intact ponatinib, mainly at the pipera-
zine moiety (Fig.  6a). Extensive biotransformation at the 
piperazine group has also been observed with imatinib in 
humans [13]. Among the metabolites generated, hydroxy-
ponatinib and N-desmethyl ponatinib were the most abun-
dant; several minor metabolites that resulted from two or 
more metabolic modifications were also identified. Four 
methylated ponatinib metabolites (M43, M46, M47, and 
M49) totaling 9.7% (of fecal TRA) were only observed 
in feces, and these metabolites were likely generated as a 
result of metabolism of ponatinib by methyl transferases 
[15, 16]. Nearly all methylation biotransformations lead to 
fewer polar metabolites, which is also true in the case of 
ponatinib.
Overall, the proposed in  vivo metabolism of ponatinib 
in humans (in plasma, urine, and feces) (Fig. 6b and Online 
Resource 5) indicates multiple biotransformation pathways. 
In vitro metabolism studies, using human liver microsomes 
and CYP-specific chemical inhibitors, have shown that 
ponatinib was metabolized mostly by CYP3A4 and to a 
lesser extent by CYP2D6 and CYP2C8 (data not shown). In 
addition, clinical drug–drug interaction studies have shown 
that co-administration of ketoconazole (a potent CYP3A4 
inhibitor) increased ponatinib Cmax and area under the con-
centration–time curve from zero to infinity  (AUC0–∞) by 
78 and 47%, respectively [11]. The major elimination path-
ways for ponatinib following a single oral administration 
are presented in Fig.  6b; they are hydroxylation (18.0%), 
N-demethylation (8.3%), methylation (8.4%), and amide 
bond hydrolysis (4.4%), among which hydroxylation and 
N-demethylation were mostly CYP3A4-mediated. These 
data indicate that ponatinib was readily absorbed and elimi-
nated through multiple pathways following administration 
of a single oral dose in healthy male subjects.
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